Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168269 | 0.91 | LTA4H (0.47) | FKBP1AACEPOLBALDH1A1CYP3A4 | |
| SCHEMBL21168268 | 0.91 | LTA4H (0.47) | FKBP1AACEPOLBALDH1A1CYP3A4 | |
| SCHEMBL21168279 | 0.86 | ACE (0.43) | FKBP1AACEALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL21168328 | 0.86 | ACE (0.43) | FKBP1AACEALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL21168332 | 0.85 | ACE (0.35) | FKBP1AACEPOLBALDH1A1CYP3A4 | |
| SCHEMBL21168276 | 0.85 | ACE (0.35) | FKBP1AACEPOLBALDH1A1CYP3A4 | |
| SCHEMBL21168327 | 0.84 | ACE (0.39) | FKBP1AACEALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL21168295 | 0.84 | ACE (0.41) | ACE | |
| SCHEMBL21168296 | 0.84 | ACE (0.41) | ACE | |
| SCHEMBL21168380 | 0.84 | FKBP1A (0.35) | FKBP1AACEALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311517-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| US-20200147054-A1 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311517-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | CD47, CD63, CD99 | FKBP1A 2991/4885ACE 4765/4885POLB 4698/4885 |
| US-20200147054-A1 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents | CD47, CD63, CD99 | FKBP1A 2991/4885ACE 4765/4885POLB 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.